Who Paid My Doc
Poteligeo
Drug Monoclonal Antibody
NDC 42747-761-01
General payments
$2,478,236
Research payments
$17,951,318
Through program year 2025, $2,478,236 in general payments and $17,951,318 in research payments were reported against Poteligeo (Monoclonal Antibody).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $398,703 | 2,876 |
| 2025 | Research | $7,205,287 | 108 |
| 2024 | General | $424,518 | 2,726 |
| 2024 | Research | $5,291,862 | 184 |
| 2023 | General | $338,923 | 3,018 |
| 2023 | Research | $2,945,539 | 135 |
| 2022 | General | $336,655 | 2,582 |
| 2022 | Research | $622,315 | 32 |
| 2021 | General | $178,567 | 1,465 |
| 2021 | Research | $377,479 | 9 |
| 2020 | General | $215,020 | 765 |
| 2020 | Research | $423,387 | 2 |
| 2019 | General | $585,849 | 1,944 |
| 2019 | Research | $1,085,450 | 100 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 57 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 50 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
15,376 general · 570 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.